Efficacy Of Baricitinib in Patients With Moderate-To-Severe Rheumatoid Arthritis Up to 6.5 Years Of Treatment: Results Of A Long-Term Study
Journal article
Caporali R. et al, (2024), Rheumatology
The impact of filgotinib on pain control in the Phase 3 FINCH studies
Journal article
TAYLOR PC. et al, (2024), Rmd open
Correction: Filgotinib Modulates Inflammation-Associated Peripheral Blood Protein Biomarkers in Adults with Active Rheumatoid Arthritis and Prior Inadequate Response to Methotrexate.
Journal article
Tanaka Y. et al, (2023), Rheumatology and therapy
Stratification of biological therapies by pathobiology in biologic-naive patients with rheumatoid arthritis (STRAP and STRAP-EU): two parallel, open-label, biopsy-driven, randomised trials
Journal article
Rivellese F. et al, (2023), The lancet rheumatology, 5, e648 - e659
Are TNF inhibitors still the agent of choice for RA?
Journal article
TAYLOR P., (2023), Nature reviews rheumatology
Therapy for Chikungunya Arthritis: A Study of 133 Brazilian Patients.
Journal article
Amaral JK. et al, (2023), Am j trop med hyg, 109, 542 - 547
Teleconsultation in Rheumatology: a literature review and opinion paper
Journal article
Avouac J. et al, (2023), Seminars in arthritis and rheumatism, 152271 - 152271
Patterns and determinants of response to novel therapies in juvenile and adult-onset polyarthritis
Journal article
Triaille C. et al, (2023), Rheumatology
Anti–GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: A Phase 3 randomised trial (contRAst 3)
Journal article
TAYLOR PC. et al, (2023), Annals of the rheumatic diseases
Anti–GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two Phase 3 randomised trials (contRAst 1 and contRAst 2)
Journal article
Fleischmann R. et al, (2023), Annals of the rheumatic diseases
Stratification of Biologic Therapies for RA by Pathobiology (STRAP/STRAP-EU): A randomised, open-labelled biopsy-driven stratification trial in DMARD inadequate responder patients randomised to Etanercept, Tocilizumab or Rituximab.
Journal article
Rivellese F. et al, (2023), The lancet rheumatology
Differential properties of Janus kinase inhibitors in the treatment of immune-mediated inflammatory diseases
Journal article
TAYLOR PC. et al, (2023), Rheumatology
Alterations in the gut microbiome implicate key taxa and metabolic pathways across inflammatory arthritis phenotypes.
Journal article
Thompson KN. et al, (2023), Sci transl med, 15
Filgotinib modulates inflammation-associated peripheral blood protein biomarkers in adults with active rheumatoid arthritis and prior inadequate response to methotrexate
Journal article
Tanaka Y. et al, (2023), Rheumatology and therapy
Predicting successful biologics tapering in patients with inflammatory arthritis: Secondary analyses based on the BIOlogical Dose OPTimisation (BIODOPT) trial
Journal article
Uhrenholt L. et al, (2023), British journal of clinical pharmacology
A JAK Inhibitor for Treatment of Rheumatoid Arthritis: The Baricitinib Experience
Journal article
TAYLOR PC. et al, (2023), Journal of clinical medicine
Correction to: A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19.
Journal article
Bieber T. et al, (2023), Adv ther
Pain and Inflammation as Mediators of Tofacitinib Treatment Effect on Fatigue in Patients with Ankylosing Spondylitis: A Mediation Analysis
Journal article
Kristensen LE. et al, (2023), Rheumatology and therapy
Predicting successful biologics tapering in patients with inflammatory arthri-tis: Secondary analyses based on the BIODOPT trial
Journal article
Uhrenholt L. et al, (2023), British journal of clinical pharmacology
Efficacy of certolizumab pegol across baseline rheumatoid factor subgroups in patients with rheumatoid arthritis: Post-hoc analysis of clinical trials.
Journal article
Tanaka Y. et al, (2023), Int j rheum dis